Workshop Day - Tuesday, December 3
Technical Stream
Strategy Stream
Workshop A <style="teht;">dsfdfsfsfasfs9.00 - 12.00
Workshop B sdfjslkdflsakjdflskfjsalkkjds 9.00 - 12.00
Progressing Lipid Nanoparticle-Based Delivery of Genome
Editing Therapies
Carlo Zambonelli, Independent LNP Expert
Jeffrey Marshall, Analytical Director, mRNA & gRNA Platforms,
Beam Therapeutics
Navigating a Crowded Market: Target Selection & Portfolio
Strategy
John Murphy, Chief Scientific Officer, Arbor Biotechnologies
Ryan Leenay, Associate Vice President, Genome Editing, Eli
Lilly
Workshop C <style="teht;">dsfdfsfsfasfs1.00 - 4.00
Workshop D sdfjslkdflsakjdflskfjsalkkjds 1.00 - 4.00
Developing Robust Nonclinical Safety Packages
Ryo Takeuchi, Senior Director, Genome Editing, Excision
BioTherapeutics
Ankit Gupta, Senior Director, Head of Gene Editing,
Affini-T Therapeutics
New FDA Guidance on Platform Technologies: Analysis,
Learnings & Implications for Gene Editing Drug Developers
Jim Wang, Vice President Regulatory Affairs, Genetic Medicine, Regeneron Pharmaceuticals
Narin Ahmed, Vice President, Regulatory Science, Tessera
Therapeutics